JP2000128790A - 抗腫瘍性物質を含有する有効沈澱物の分取方法 - Google Patents
抗腫瘍性物質を含有する有効沈澱物の分取方法Info
- Publication number
- JP2000128790A JP2000128790A JP10320060A JP32006098A JP2000128790A JP 2000128790 A JP2000128790 A JP 2000128790A JP 10320060 A JP10320060 A JP 10320060A JP 32006098 A JP32006098 A JP 32006098A JP 2000128790 A JP2000128790 A JP 2000128790A
- Authority
- JP
- Japan
- Prior art keywords
- precipitate
- blood
- substance
- cooling tank
- supernatant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002244 precipitate Substances 0.000 title claims abstract description 107
- 239000000126 substance Substances 0.000 title claims abstract description 64
- 230000000259 anti-tumor effect Effects 0.000 title claims description 22
- 210000004369 blood Anatomy 0.000 claims abstract description 92
- 239000008280 blood Substances 0.000 claims abstract description 92
- 238000001816 cooling Methods 0.000 claims abstract description 51
- 239000006228 supernatant Substances 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 32
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 28
- 229940127219 anticoagulant drug Drugs 0.000 claims abstract description 28
- 238000006243 chemical reaction Methods 0.000 claims abstract description 28
- 238000001556 precipitation Methods 0.000 claims abstract description 22
- 239000007788 liquid Substances 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 238000002156 mixing Methods 0.000 claims abstract description 11
- 239000000463 material Substances 0.000 claims abstract description 9
- 239000007858 starting material Substances 0.000 claims description 31
- 238000003860 storage Methods 0.000 claims description 22
- 230000015572 biosynthetic process Effects 0.000 claims description 21
- 238000005194 fractionation Methods 0.000 claims description 21
- 239000013049 sediment Substances 0.000 claims description 17
- 238000003756 stirring Methods 0.000 claims description 16
- 239000013076 target substance Substances 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000012134 supernatant fraction Substances 0.000 claims description 7
- 238000005381 potential energy Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract description 19
- 241000124008 Mammalia Species 0.000 abstract description 9
- 206010018910 Haemolysis Diseases 0.000 abstract description 8
- 230000008588 hemolysis Effects 0.000 abstract description 8
- 239000013543 active substance Substances 0.000 abstract description 5
- 230000007423 decrease Effects 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 241000894006 Bacteria Species 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 239000000306 component Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 6
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 6
- 235000011130 ammonium sulphate Nutrition 0.000 description 6
- 238000010241 blood sampling Methods 0.000 description 6
- 210000005260 human cell Anatomy 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 208000001382 Experimental Melanoma Diseases 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102100033041 Carbonic anhydrase 13 Human genes 0.000 description 1
- 102100033007 Carbonic anhydrase 14 Human genes 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000867860 Homo sapiens Carbonic anhydrase 13 Proteins 0.000 description 1
- 101000867862 Homo sapiens Carbonic anhydrase 14 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 235000014705 isoleucine Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- IBIRZFNPWYRWOG-UHFFFAOYSA-N phosphane;phosphoric acid Chemical compound P.OP(O)(O)=O IBIRZFNPWYRWOG-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10320060A JP2000128790A (ja) | 1998-10-23 | 1998-10-23 | 抗腫瘍性物質を含有する有効沈澱物の分取方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10320060A JP2000128790A (ja) | 1998-10-23 | 1998-10-23 | 抗腫瘍性物質を含有する有効沈澱物の分取方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000128790A true JP2000128790A (ja) | 2000-05-09 |
| JP2000128790A5 JP2000128790A5 (OSRAM) | 2005-11-04 |
Family
ID=18117280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10320060A Pending JP2000128790A (ja) | 1998-10-23 | 1998-10-23 | 抗腫瘍性物質を含有する有効沈澱物の分取方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2000128790A (OSRAM) |
-
1998
- 1998-10-23 JP JP10320060A patent/JP2000128790A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4754218B2 (ja) | タンパク質含有原料の加水分解のための装置および方法ならびに得られた加水分解産物の用途 | |
| US20070199903A1 (en) | System For Removing Solids From Aqueous Solutions | |
| US20070221552A1 (en) | System for Processing a Biomaterial Waste Stream | |
| US20070175825A1 (en) | System for the treating biomaterial waste streams | |
| JPH0457351B2 (OSRAM) | ||
| US20070218541A1 (en) | Fermenter And Fermentation Method | |
| EP2777388B1 (en) | Method and device for producing starting material milk for skim milk | |
| US20070227971A1 (en) | Flocculation Method and Flocculated Organism | |
| NZ553206A (en) | Method for production of peptides/amino acids from animal and aquatic material using natural decomposing enzymes | |
| CN104479995B (zh) | 羊皮胶原蛋白提取系统及提取方法 | |
| CN102917598A (zh) | 红肉脂肪减少过程中非凝固产品的回收 | |
| JP2000128790A (ja) | 抗腫瘍性物質を含有する有効沈澱物の分取方法 | |
| CN1977013A (zh) | 用于制备和纯化明胶的方法 | |
| CN1552891A (zh) | 一种乳源ace抑制肽的制备方法 | |
| CN108484753A (zh) | 一种鹿皮蛋白低聚肽的工业化生产工艺 | |
| JP4303822B2 (ja) | 抗腫瘍性物質の製造方法 | |
| CN109172607B (zh) | 一种鲜驴胎盘提取胎盘素的工艺及方法 | |
| US4350624A (en) | Method for recovering meat proteins remaining attached to the bones after the boning operation | |
| CN106727711A (zh) | 一种纳米技术在羊胚胎提取中的应用以及羊胚胎素的质量标准 | |
| CN113201522B (zh) | 一种蛋白酶的精制和干燥方法 | |
| CN108396050A (zh) | 一种猪蹄蛋白低聚肽的工业化生产工艺 | |
| JPH023466B2 (OSRAM) | ||
| CN108179168A (zh) | 一种鹿心蛋白低聚肽的工业化生产工艺 | |
| CN221413346U (zh) | 一种牛肉营养物质的提取装置 | |
| Elliot et al. | A continuous process for the production of purified porcine γ-globulin for use in pig-milk replacer supplements |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050914 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050914 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090512 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091006 |